Novartis

Aktuelle Nachrichten

Schlagzeilen in der Originalsprache der Quelle.

• Novartis signs mRNA deal for about $7.8 billion with China's Abogen (öffnet in neuem Tab)

  Reuters · 02.10.2026

• Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager (öffnet in neuem Tab)

  Fierce Biotech · 02.10.2026

• 
  Novartis (NVS) Has More Growth Ahead. Can its Portfolio Outrun Generic Pressure? (öffnet in neuem Tab)

  Insider Monkey · 28.09.2026

• 
  Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover? (öffnet in neuem Tab)

  Insider Monkey · 26.09.2026

• Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines (öffnet in neuem Tab)

  Stocktwits · 26.09.2026

• A Top Novartis (NVS) Shareholder Says ‘The Party is Over’ for its Dealmaking Team (öffnet in neuem Tab)

  Yahoo Finance · 25.09.2026

• Health Care Roundup: Market Talk (öffnet in neuem Tab)

  The Wall Street Journal · 25.09.2026

• Novartis (SWX:NOVN) Lands Global Radioligand Therapy License To Deepen Cancer Pipeline (öffnet in neuem Tab)

  Simply Wall St. · 25.09.2026

• Novartis Fends Off Antitrust Suit Over Heart Drug’s FDA Status (öffnet in neuem Tab)

  Bloomberg Law News · 24.09.2026

• Roche targets Novartis on IgAN market after Phase III win (öffnet in neuem Tab)

  Clinical Trials Arena · 24.09.2026

• Failure of Novartis’ Pelacarsen Could Reshape the Lp(a) Race for CRISPR and Ionis (öffnet in neuem Tab)

  Insider Monkey · 24.09.2026

• MSD’s DME drug could challenge anti-VEGF reign, late-stage study suggests (öffnet in neuem Tab)

  Clinical Trials Arena · 24.09.2026

• Will Vertex's Kidney Disease Pipeline Be a New Growth Engine? (öffnet in neuem Tab)

  Zacks · 24.09.2026

• Roche Drops as Phase 3 Kidney Signal Needs Two-Year Proof (öffnet in neuem Tab)

  GuruFocus.com · 23.09.2026

• Amgen price target raised by Jefferies to $410 after positive Sjögren's data (öffnet in neuem Tab)

  Proactive · 23.09.2026

• Roche, Ionis RNA drug scores in kidney disease study (öffnet in neuem Tab)

  BioPharma Dive · 23.09.2026

• Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs (öffnet in neuem Tab)

  Zacks · 23.09.2026

• European big pharma unites amid ‘ringing alarm bells’ of continent’s dominance (öffnet in neuem Tab)

  Clinical Trials Arena · 23.09.2026

• BoomRay and Novartis sign $900m deal for radioligand therapy (öffnet in neuem Tab)

  Pharmaceutical Technology · 23.09.2026

• Novartis defeats drug-purchaser lawsuit over delay of Entresto generics (öffnet in neuem Tab)

  Reuters · 23.09.2026

• Novartis bets up to $900M for radioligand therapy from China’s BoomRay (öffnet in neuem Tab)

  BioSpace · 23.09.2026

• Roche’s phase 3 win tees up fight with Novartis for blockbuster kidney disease market (öffnet in neuem Tab)

  Fierce Biotech · 23.09.2026

• AstraZeneca and GSK warn Europe’s drug industry is ‘at risk’ (öffnet in neuem Tab)

  The Telegraph · 22.09.2026

• European drugmakers call for faster trials, more spending to compete with US, China (öffnet in neuem Tab)

  Reuters · 22.09.2026

• Novartis secures new radioligand in $900M deal as competition strengthens (öffnet in neuem Tab)

  Fierce Biotech · 22.09.2026

• Morgan Stanley flags Amgen's edge after heart-drug rival stumbles (öffnet in neuem Tab)

  TheStreet · 22.09.2026

• Novartis (NVS) Faces Another Pipeline Setback as ALS Drug Fails Mid-Stage Trial (öffnet in neuem Tab)

  Insider Monkey · 22.09.2026

• Telix Beefs Up Radioisotopes Supply With $2.35 Billion Deal; Shares Crash (öffnet in neuem Tab)

  Investor's Business Daily · 21.09.2026

• NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication (öffnet in neuem Tab)

  Zacks · 21.09.2026

• Novo Nordisk shares plunge over 7% as new targets fail to reassure investors (öffnet in neuem Tab)

  Proactive · 21.09.2026